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A toxic gas eases IBD
 
A study on page 1703 might help explain why active smokers 
rarely suffer from an inflammatory bowel disease (IBD) known 
as ulcerative colitis. Hegazi and colleagues show that carbon 
monoxide (CO) gas, a component of cigarette smoke, shuts down 
the production of a disease-promoting cytokine, thus easing 
chronic bowel inflammation in mice.
CO is both a toxic air pollutant and a normal byproduct of 
cellular heme metabolism. Although CO’s asphyxiant properties 
have earned it a bad reputation, the ubiquitous tissue expression 
of the natural CO-producing enzyme heme oxygenase-1 (HO-1) 
suggests that the effects of CO must not be all bad.
Indeed, recent studies have shown that CO, at least at low 
concentrations, has a redeeming quality: it acts as an 
antiinflammatory agent. Low dose inhaled CO is therapeutic in 
many acute disease models including bacterial sepsis, organ 
transplantation, and vascular injury. Normally, HO-1 expression 
(and thus CO production) is induced under conditions of cellular 
stress, such as infection or oxygen deprivation, probably to limit 
the adverse effects of stress-induced inflammation.
The effects of CO on chronic inflammation, however, had not been 
studied. Here, Hegazi and colleagues show that CO exposure also 
inhibits chronic intestinal inflammation in mice. Exogenous CO 
treatment induced the expression of HO-1, either directly or indirectly, 
which in turn limited the intestinal production of the inflammation-
inducing cytokine interleukin (IL)-12. In macrophages, HO-1 inhibited 
the expression of the transcription factor IRF-8 (interferon regulatory 
factor-8), which normally drives the synthesis of IL-12 in response to 
bacterial lipopolysaccharide and interferon-
 
 
 
—a situation that mimics 
the stimulation of these cells in the inflamed intestine.
Although the induction of HO-1 is required for the therapeutic 
effects of CO in most disease models, this is the first study to 
identify IRF-8 as a target of HO-1–induced inhibition. How HO-1 
represses IRF-8 expression remains to be determined.
Based on these results, the authors suggest that inhaled 
CO or agents that increase endogenous HO-1 activity might 
be therapeutic in patients with ulcerative colitis. However, 
nonsmokers with IBD shouldn’t necessarily break out the Marlboros, 
as cigarette smoking is a risk factor not only for heart disease and 
cancer but also for Crohn’s disease, another form of IBD. 
Inhaled carbon monoxide induces the intestinal expression of heme 
oxygenase-1 (dark brown) and soothes colitis.
 
New hope for tumor vaccines
 
The way a tumor cell dies determines
its immune-stimulating capacity, ac-
cording to a study by Casares and col-
leagues on page 1691. Tumor cells that
die from exposure to the chemotherapy
drug doxorubicin, they show, become
highly immunogenic and induce the
regression of established tumors when
injected into mice.
Inactivated tumor cells have long
been considered to be attractive vaccine
immunogens, in part because whole-cell
vaccines would allow each patient to be
immunized against his or her own tumor. But this approach
has met with limited success, probably because traditional
ways of inducing tumor cell death—by irradiation or freeze-
thawing—somehow strip the cells of their immunogenicity.
Many vaccine strategists have instead turned to T cell-
inducing dendritic cell (DC) vaccines, in which DCs are
grown from a patient’s blood, pulsed with tumor antigens,
and reinjected. But the new data by Casares and colleagues
might help revive interest in the simpler whole-cell approach.
Casares et al. show that tumor cells treated
with doxorubicin, but not those treated
with the chemotherapy drug mitomy-
cin, elicit a tumor-specific T cell response
in mice. Although both treatments induced
apoptosis of the injected tumor cells, only
the doxorubicin-treated cells were taken
up by DCs, which then activated specific
T cells. The immune-stimulating effect of
doxorubicin required the activity of the
death-inducing caspase enzymes in the tu-
mor cells, although the relevant caspase
targets were not identified.
The authors are now trying to pin
down the doxorubicin-induced changes
on the dying tumor cells that render them
more palatable to DCs. In the meantime,
they suggest that this approach—should it
work in humans—might provide a more
practical alternative to anticancer vaccine
strategies that require the labor-intensive
cultivation of autologous DCs. 
Tumor growth is blunted in mice immunized 
with doxorubicin-treated cells.
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